Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
14 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Financiado por un miembro del IRDiRC = 
; Miembro de una ERN = 
Ensayo(s) clínico(s) nacional(es)
ALEMANIA
Baden-Württemberg
ULM
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
ALEMANIA
Bayern
MÜNCHEN
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
LMU Klinikum der Universität München - Campus Großhadern
Institut für Klinische Neuroimmunologie
ALEMANIA
Bayern
WÜRZBURG
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg
Neurologische Klinik und Poliklinik
ALEMANIA
Berlin
BERLIN
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Charité - Universitätsmedizin Berlin (CCM)
Klinik für Neurologie (CCM)
ALEMANIA
Niedersachsen
HANNOVER
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Medizinische Hochschule Hannover
Abteilung Klinische Neuroimmunologie und Neurochemie
ALEMANIA
Nordrhein-Westfalen
BOCHUM
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Neurologisches Universtätsklinikum im St. Josef-Hospital
Klinik für Neurologie
ALEMANIA
Nordrhein-Westfalen
MÜNSTER
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsklinikum Münster
Klinik für Neurologie mit Institut für Translationale Neurologie
ALEMANIA
Rheinland-Pfalz
MAINZ
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsmedizin Mainz
Klinik und Poliklinik für Neurologie
ALEMANIA
Schleswig-Holstein
KIEL
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Neurologie
ALEMANIA
Thüringen
JENA
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsklinikum Jena
Hans-Berger-Klinik für Neurologie
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
University of Cambridge
Department of Medicine
REINO UNIDO (EL)
Oxfordshire
OXFORD
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
John Radcliffe Hospital
Oxford University Hospitals NHS Trust
ITALIA
TOSCANA
FIRENZE
Efficacy of ketamine in refractory convulsive status epilepticus in children: a multicenter, randomized, controlled, open-label, no-profit, with sequential design study
Azienda Ospedaliera Universitaria Anna Meyer
Neurologia Pediatrica
FRANCIA
ILE-DE-FRANCE
PARIS